The abstract is read at the publisher; the summary is JClub's.
Amyloid-targeting therapies in Alzheimer disease patients with suspected copathologies require individualized clinical decisions because evidence is incomplete and prospective data are needed.
- Why it matters: Clinicians face uncertainty about how amyloid-targeting treatments should be used when non-Alzheimer disease copathologies may be present, creating a gap in guidance.
- What they did: This Viewpoint reviews how to approach treatment selection in Alzheimer disease patients with suspected copathologies and highlights where current evidence is lacking, calling for prospective studies.
- The result: The discussion implies that better prospective research is necessary to clarify appropriate use of amyloid-targeting therapies in this specific patient subgroup.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.